tiprankstipranks
Astellas Pharma Inc (JP:4503)
TSE/TYO:4503
Holding JP:4503?
Track your performance easily

Astellas Pharma (4503) Stock Price & Analysis

3 Followers

4503 Stock Chart & Stats


Options Prices

Currently, No data available
---

Ownership Overview

7.48%83.32%
Insiders
― Other Institutional Investors
83.32% Public Companies and
Individual Investors

4503 FAQ

What was Astellas Pharma Inc’s price range in the past 12 months?
Astellas Pharma Inc lowest stock price was ¥1426.00 and its highest was ¥1839.50 in the past 12 months.
    What is Astellas Pharma Inc’s market cap?
    Currently, no data Available
    When is Astellas Pharma Inc’s upcoming earnings report date?
    Astellas Pharma Inc’s upcoming earnings report date is Jan 30, 2025 which is in 69 days.
      How were Astellas Pharma Inc’s earnings last quarter?
      Astellas Pharma Inc released its earnings results on Oct 30, 2024. The company reported ¥20.06 earnings per share for the quarter, beating the consensus estimate of ¥18.013 by ¥2.047.
        Is Astellas Pharma Inc overvalued?
        According to Wall Street analysts Astellas Pharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Astellas Pharma Inc pay dividends?
          Astellas Pharma Inc pays a Annually dividend of ¥37 which represents an annual dividend yield of 5%. See more information on Astellas Pharma Inc dividends here
            What is Astellas Pharma Inc’s EPS estimate?
            Astellas Pharma Inc’s EPS estimate is ¥18.49.
              How many shares outstanding does Astellas Pharma Inc have?
              Astellas Pharma Inc has 1,809,663,100 shares outstanding.
                What happened to Astellas Pharma Inc’s price movement after its last earnings report?
                Astellas Pharma Inc reported an EPS of ¥20.06 in its last earnings report, beating expectations of ¥18.013. Following the earnings report the stock price went down -0.084%.
                  Which hedge fund is a major shareholder of Astellas Pharma Inc?
                  Currently, no hedge funds are holding shares in JP:4503
                  ---

                  Astellas Pharma Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  Astellas Pharma Inc

                  Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
                  ---

                  4503 Company Deck

                  ---

                  4503 Earnings Call

                  Q2 2024
                  0:00 / 0:00
                  ---

                  4503 Stock 12 Month Forecast

                  Average Price Target

                  ¥1,958.14
                  ▲(24.56% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1491":"¥1,491","1800":"¥1,800","2109":"¥2,109","1645.5":"¥1,645.5","1954.5":"¥1,954.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2108.66415516666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1958.14296153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥1.96K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1757.22012930555,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.76K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1491,1645.5,1800,1954.5,2109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1806.6664734743586,1831.8329469487169,1856.9994204230754,1882.1658938974338,1907.3323673717923,1932.4988408461506,1957.6653143205092,1982.8317877948675,2007.998261269226,2033.1647347435844,2058.3312082179427,2083.4976816923013,{"y":2108.66415516666,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1795.0879201176924,1808.6758402353846,1822.263760353077,1835.8516804707692,1849.4396005884616,1863.0275207061538,1876.6154408238463,1890.2033609415384,1903.7912810592309,1917.379201176923,1930.9671212946155,1944.5550414123077,{"y":1958.14296153,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1779.6323176388885,1777.764635277777,1775.8969529166654,1774.029270555554,1772.1615881944424,1770.2939058333309,1768.4262234722191,1766.5585411111076,1764.690858749996,1762.8231763888846,1760.955494027773,1759.0878116666615,{"y":1757.22012930555,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1731.063,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1615.595,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1621.344,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1604.575,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1605.679,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1492.175,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1515.169,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1554.309,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1621.334,"date":1720742400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1707.44,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1762.235,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1728,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1781.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Astellas Pharma
                  Takeda Pharmaceutical Company
                  Sanofi
                  Novartis
                  Bayer

                  Best Analysts Covering 4503

                  1 Year
                  Miki SogiBernstein
                  1 Year Success Rate
                  0/3 ratings generated profit
                  0%
                  1 Year Average Return
                  -10.30%
                  reiterated a buy rating 4 days ago
                  Copying Miki Sogi's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -10.30% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis